(VIANEWS) – CEGEDIM (CGM.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| CEGEDIM (CGM.PA) | €16.46 | 2.97% | 5.4% |
| UCB (UCB.BR) | €80.36 | 1.65% | 4.81% |
| SARTORIUS STED BIO (DIM.PA) | €311.30 | 0.47% | 41.43% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. CEGEDIM (CGM.PA)
2.97% Forward Dividend Yield and 5.4% Return On Equity
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 14.96. Meaning, the purchaser of the share is investing €14.96 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.4%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.5%, now sitting on 541.11M for the twelve trailing months.
More news about CEGEDIM.
2. UCB (UCB.BR)
1.65% Forward Dividend Yield and 4.81% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €3.77.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 21.32. Meaning, the purchaser of the share is investing €21.32 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.81%.
More news about UCB.
3. SARTORIUS STED BIO (DIM.PA)
0.47% Forward Dividend Yield and 41.43% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €4.31.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 72.23. Meaning, the purchaser of the share is investing €72.23 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.43%.
More news about SARTORIUS STED BIO.
